Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Lipidomic Profiling of Plasma Samples in Patients with Newly Diagnosed Multiple Myeloma; A Biomarker Study for Predicting the Response and Toxicities of Melphalan, Prednisolone and Bortezomib (MPB) Regimen : An Ancillary Study of the JCOG1105 (JCOG1105A1)

Masaki Ri, Shinsuke Iida, MD PhD, Dai Maruyama, MD PhD, Kosuke Saito, Yoshiro Saito, Satoshi Osaga, Masahiro Tohkin, Naoki Miyata, Kensei Tobinai, MD PhD, Noriko Fukuhara, MD PhD, Kana Miyazaki, MD PhD, Yosuke Minami, MD PhD, Norifumi Tsukamoto, MD PhD, Hideki Tsujimura, MD PhD, Makoto Yoshimitsu, MD PhD, Kenichi Miyamoto, Kunihiro Tsukasaki, MD PhD, Hirokazu Nagai, MD PhD

Blood (2019) 134 (Supplement_1): 3156.

https://doi.org/10.1182/blood-2019-122218

Published: 2019

Journal Articles

Impact of Total Dose Intensity and Relative Dose Intensity (RDI) of R-CHOP on Survival in Patients with DLBCL

Ayumi Komuro, Sachiko Seo, MD PhD, Nobuo Mochizuki, Yosuke Minami, MD PhD, Toshikatu Kawasaki

Blood (2018) 132 (Supplement 1): 4218.

https://doi.org/10.1182/blood-2018-99-114227

Published: 2018

Journal Articles

Biomarker and Gene Profiling Analyses in Acute Myeloid Leukemia during Treatment with Hedgehog Signaling Inhibitor

Seiji Kakiuchi, MD, Yosuke Minami, MD PhD, Nobuaki Fukushima, MD, Hiroshi Matsuoka, MD PhD, Tomoki Naoe, MD PhD, Hironobu Minami, MD D.MDSci.

Blood (2015) 126 (23): 1263.

https://doi.org/10.1182/blood.V126.23.1263.1263

Published: 2015

Journal Articles

Efficacy of the Two-Dose Influenza Vaccine in Cancer Patients Receiving Chemotherapy: A Prospective Study

Blood (2014) 124 (21): 4131.

https://doi.org/10.1182/blood.V124.21.4131.4131

Published: 2014

Journal Articles

Discontinuation Of Dasatinib In Patients With CML Who Have Maintained Complete Molecular Response For At Least One Year: Results From a Prospective Discontinuation (DADI) Trial

Blood (2013) 122 (21): 3998.

https://doi.org/10.1182/blood.V122.21.3998.3998

Published: 2013

Journal Articles

Treatment With Hedgehog Inhibitor, PF-04449913, Attenuates Leukemia-Initiation Potential In Acute Myeloid Leukemia Cells

Nobuaki Fukushima, MD, Yosuke Minami, MD, PhD, Fumihiko Hayakawa, MD, PhD, Hitoshi Kiyoi, MD, PhD, Anil Sadarangani, PhD, Catriona HM Jamieson, MD, PhD, Tomoki Naoe, MD, PhD

Blood (2013) 122 (21): 1649.

https://doi.org/10.1182/blood.V122.21.1649.1649

Published: 2013

Journal Articles

Targeting The Dopamine Receptor Signaling Limits The Self-Renewal Of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

Tetsuzo Tauchi, MD, Seiichiro Katagiri, MD, Seiichi Okabe, M.D., Yosuke Minami, MD, PhD, Tomoki Naoe, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2013) 122 (21): 1298.

https://doi.org/10.1182/blood.V122.21.1298.1298

Published: 2013

Journal Articles

Wnt Signaling Is Associated with Anti-Apoptosis in the Interaction Between Acute Myeloid Leukemia Cells and Stromal Cells

Yosuke Minami, MD, PhD, Yosuke Niwa, Akihiro Abe, MD, PhD, Fumihiko Hayakawa, MD, PhD, Tomoki Naoe, MD, PhD

Blood (2012) 120 (21): 1366.

https://doi.org/10.1182/blood.V120.21.1366.1366

Published: 2012

Journal Articles

Targeting the Hedgehog Signaling Pathway Limits the Self-Renewal of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

Tetsuzo Tauchi, M.D., Seiichiro Katagiri, M.D., Seiichi Okabe, M.D., Yosuke Minami, MD, PhD, Tomoki Naoe, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2012) 120 (21): 531.

https://doi.org/10.1182/blood.V120.21.531.531

Published: 2012

Journal Articles

Retention of Slow-Cycling CD34 + cells During Imatinib Treatment and Rapid Decline After 2nd ABL-TKI Treatment in Ph + Leukemia Cells

Yosuke Minami, MD, PhD, Akihiro Abe, Miho Minami, Yachiyo Kuwatsuka, Nobuaki Fukushima, Kunio Kitamura, Junji Hiraga, MD, PhD, Kazuhito Yamamoto, MD, PhD, Catriona Jamieson, Tomoki Naoe, MD, PhD

Blood (2011) 118 (21): 641.

https://doi.org/10.1182/blood.V118.21.641.641

Published: 2011

Journal Articles

Treatment with the PI3K/mTOR Inhibitor, NVP-BEZ235, Overcomes Resistance to Imatinib in Quiescent or T315I-Mutated Ph + Leukemia Cells,

Yosuke Minami, MD, PhD, Miho Minami, Nobuaki Fukushima, Yachiyo Kuwatsuka, Tomoki Naoe, MD, PhD

Blood (2011) 118 (21): 3488.

https://doi.org/10.1182/blood.V118.21.3488.3488

Published: 2011

Journal Articles

PAX5-PML Acts as a Dual Dominant-Negative Form of PAX5 and PML

Shingo Kurahashi, MD, Fumihiko Hayakawa, MD, PhD, Yasuhiko Miyata, MD, PhD, Yosuke Minami, MD, PhD, Akihiro Abe, MD, PhD, Tomoki Naoe, MD, PhD

Blood (2010) 116 (21): 3227.

https://doi.org/10.1182/blood.V116.21.3227.3227

Published: 2010

Journal Articles

Treatment with mTOR Inhibitor, Everolimus (RAD001) Overcomes Resistance to Imatinib In Ph-Leukemia Quiescent Cells.

Yachiyo Kuwatsuka, MD, Yosuke Minami, MD, PhD, Miho Minami, Ryohei Tanizaki, Hitoshi Kiyoi, MD, PhD, Tomoki Naoe, MD, PhD

Blood (2010) 116 (21): 1579.

https://doi.org/10.1182/blood.V116.21.1579.1579

Published: 2010

Journal Articles

Biomarkers In Cell Death of Imatinib-Resistant Ph-Leukemia Cells During Treatment with mTOR Inhibitor, Everolimus

Miho Minami, Yosuke Minami, MD, PhD, Yachiyo Kuwatsuka, MD, Hitoshi Kiyoi, MD, PhD, Tomoki Naoe, MD, PhD

Blood (2010) 116 (21): 3988.

https://doi.org/10.1182/blood.V116.21.3988.3988

Published: 2010

Journal Articles

Rapid Reduction of Chronic Myeloid Leukemia Stem Cells After Treatment with Second-Generation BCR-ABL Kinase Inhibitors, Dasatinib and Nilotinib

Yosuke Minami, MD, PhD, Akihiro Abe, Yuka Nomura, Miho Minami, Yachiyo Kuwatsuka, Kunio Kitamura, Junji Hiraga, Shinichi Mizuno, Kazuhito Yamamoto, Tomohiro Kajiguchi, Masashi Sawa, Yuichiro Inagaki, Toshiya Yokozawa, Etsuko Aoki, Kazutaka Ozeki, Keisuke Watanabe, Koichi Miyamura, Hitoshi Kiyoi, Tomoki Naoe

Blood (2010) 116 (21): 4457.

https://doi.org/10.1182/blood.V116.21.4457.4457

Published: 2010

Journal Articles

Treatment with Bortezomib Overcomes Resistance to Imatinib in Ph-Leukemia Quiescent Cells.

Yachiyo Kuwatsuka, MD, Yosuke Minami, MD, PhD, Ryohei Tanizaki, MS, Miho Minami, Akihiro Abe, MD, PhD, Yuka Nomura, Hitoshi Kiyoi, Tomoki Naoe, MD, PhD

Blood (2009) 114 (22): 1426.

https://doi.org/10.1182/blood.V114.22.1426.1426

Published: 2009

Journal Articles

PAX5-PML Acts as a Dual Dominant-Negative Form of Both PAX5 and PML.

Shingo Kurahashi, MD, Fumihiko Hayakawa, MD, PhD, Yasuhiko Miyata, MD, PhD, Yosuke Minami, MD, PhD, Akihiro Abe, MD, PhD, Tomoki Naoe, MD, PhD

Blood (2009) 114 (22): 3070.

https://doi.org/10.1182/blood.V114.22.3070.3070

Published: 2009

Journal Articles

Treatment with mTOR Inhibitor, Everolimus (RAD001) Overcomes Resistance to Imatinib in Ph-Leukemia Quiescent or T315I-Mutated Cells.

Yosuke Minami, MD, PhD, Miho Minami, Yachiyo Kuwatsuka, MD, Ryohei Tanizaki, MS, Yuka Nomura, Akihiro Abe, MD, PhD, Hitoshi Kiyoi, MD, PhD, Tomoki Naoe, MD, PhD

Blood (2009) 114 (22): 3277.

https://doi.org/10.1182/blood.V114.22.3277.3277

Published: 2009

Journal Articles

KW-2449, a Novel Multi-Kinase Inhibitor, Suppresses the Growth of Imatinib-Resistant Ph+ Leukemia Including BCR-ABL/T315I Both in Vitro and in Vivo.

Yukimasa Shiotsu, PhD, Hitoshi Kiyoi, MD, PhD, Ryohei Tanizaki, MD, PhD, Yosuke Minami, MD, PhD, Akihiro Abe, MD, PhD, Yuichi Ishikawa, MD, PhD, Kenichi Ishii, Makiko Shimizu, Yutaka Kanda, PhD, Yuko Sato, MD, PhD, Shiro Akinaga, PhD, Jorge Cortes, MD, Tomoki Naoe, MD, PhD

Blood (2008) 112 (11): 1640.

https://doi.org/10.1182/blood.V112.11.1640.1640

Published: 2008

Journal Articles

Treatment with Hsp90 Inhibitor, 17-AAG Overcomes Resistance to Small Molecule FLT3-Inhibitors in FLT3/ITD-Positive Leukemia Cells Harboring N676K-Mutation.

Yosuke Minami, MD, PhD, Yuka Nomura, Akihiro Abe, MD, PhD, Ryohei Tanizaki, MS, Yachiyo Kuwatsuka, Hitoshi Kiyoi, MD, PhD, Tomoki Naoe, MD

Blood (2008) 112 (11): 1619.

https://doi.org/10.1182/blood.V112.11.1619.1619

Published: 2008

NARROW

Lipidomic Profiling of Plasma Samples in Patients with Newly Diagnosed Multiple Myeloma; A Biomarker Study for Predicting the Response and Toxicities of Melphalan, Prednisolone and Bortezomib (MPB) Regimen : An Ancillary Study of the JCOG1105 (JCOG1105A1)

Impact of Total Dose Intensity and Relative Dose Intensity (RDI) of R-CHOP on Survival in Patients with DLBCL

Biomarker and Gene Profiling Analyses in Acute Myeloid Leukemia during Treatment with Hedgehog Signaling Inhibitor

Efficacy of the Two-Dose Influenza Vaccine in Cancer Patients Receiving Chemotherapy: A Prospective Study

Discontinuation Of Dasatinib In Patients With CML Who Have Maintained Complete Molecular Response For At Least One Year: Results From a Prospective Discontinuation (DADI) Trial

Treatment With Hedgehog Inhibitor, PF-04449913, Attenuates Leukemia-Initiation Potential In Acute Myeloid Leukemia Cells

Targeting The Dopamine Receptor Signaling Limits The Self-Renewal Of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

Wnt Signaling Is Associated with Anti-Apoptosis in the Interaction Between Acute Myeloid Leukemia Cells and Stromal Cells

Targeting the Hedgehog Signaling Pathway Limits the Self-Renewal of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

Retention of Slow-Cycling CD34 + cells During Imatinib Treatment and Rapid Decline After 2nd ABL-TKI Treatment in Ph + Leukemia Cells

Treatment with the PI3K/mTOR Inhibitor, NVP-BEZ235, Overcomes Resistance to Imatinib in Quiescent or T315I-Mutated Ph + Leukemia Cells,

PAX5-PML Acts as a Dual Dominant-Negative Form of PAX5 and PML

Treatment with mTOR Inhibitor, Everolimus (RAD001) Overcomes Resistance to Imatinib In Ph-Leukemia Quiescent Cells.

Biomarkers In Cell Death of Imatinib-Resistant Ph-Leukemia Cells During Treatment with mTOR Inhibitor, Everolimus

Rapid Reduction of Chronic Myeloid Leukemia Stem Cells After Treatment with Second-Generation BCR-ABL Kinase Inhibitors, Dasatinib and Nilotinib

Treatment with Bortezomib Overcomes Resistance to Imatinib in Ph-Leukemia Quiescent Cells.

PAX5-PML Acts as a Dual Dominant-Negative Form of Both PAX5 and PML.

Treatment with mTOR Inhibitor, Everolimus (RAD001) Overcomes Resistance to Imatinib in Ph-Leukemia Quiescent or T315I-Mutated Cells.

KW-2449, a Novel Multi-Kinase Inhibitor, Suppresses the Growth of Imatinib-Resistant Ph+ Leukemia Including BCR-ABL/T315I Both in Vitro and in Vivo.

Treatment with Hsp90 Inhibitor, 17-AAG Overcomes Resistance to Small Molecule FLT3-Inhibitors in FLT3/ITD-Positive Leukemia Cells Harboring N676K-Mutation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only